ergomar sublingual- ergotamine tartrate tablet
tersera therapeutics, llc - ergotamine tartrate (unii: mru5xh3b48) (ergotamine - unii:pr834q503t) - ergomar® is indicated as therapy to abort or prevent vascular headache, e.g., migraine, migraine variants or so-called "histaminic cephalalgia". coadministration of ergotamine with potent cyp 3a4 inhibitors (ritonavir, nelfinavir, indinavir, erythromycin, clarithromycin and troleandomycin) has been associated with acute ergot toxicity (ergotism) characterized by vasospasm and ischemia of the extremities (see precautions: drug interactions ), with some cases resulting in amputation. there have been rare reports of cerebral ischemia in patients on protease inhibitor therapy when ergotamine was coadministered, at least one resulting in death. because of the increased risk for ergotism and other serious vasospastic adverse events, ergotamine use is contraindicated with these drugs and other potent inhibitors of cyp 3a4 (e.g., ketoconazole, itraconazole) (see warnings: cyp 3a4 inhibitors ). ergomar® sublingual tablets may cause fetal harm when administered to pregnant women. ergomar® subli
trudhesa- dihydroergotamine mesylate spray, metered
impel pharmaceuticals inc. - dihydroergotamine mesylate (unii: 81axn7r2qt) (dihydroergotamine - unii:436o5hm03c) - trudhesa is indicated for the acute treatment of migraine with or without aura in adults. limitations of use trudhesa is not indicated for the preventive treatment of migraine. trudhesa is not indicated for the management of hemiplegic or basilar migraine. trudhesa is contraindicated in patients: - with concomitant use of strong cyp3a4 inhibitors, such as protease inhibitors (e.g., ritonavir, nelfinavir, or indinavir), macrolide antibiotics (e.g., erythromycin or clarithromycin), and antifungals (ketoconazole or itraconazole) [see warnings and precautions (5.1) and drug interactions (7.1)] - with ischemic heart disease (angina pectoris, history of myocardial infarction, or documented silent ischemia) or patients who have clinical symptoms or findings consistent with coronary artery vasospasm, including prinzmetal's variant angina [see warnings and precautions (5.4)] - with uncontrolled hypertension [see warnings and precautions (5.5)] - with peripheral arterial disease - with sepsis - following vascular surge
cafergot tablets 1 milligram
novartis pharmaceuticals uk ltd - ergotamine tartrate caffeine - tablets - 1 milligram
cafergot suppositories 2 milligram
novartis pharmaceuticals uk ltd - ergotamine tartrate caffeine - suppositories - 2 milligram
cafergot pb
novartis new zealand ltd - atropa belladonna 0.25mg; butalbital 100mg; caffeine 100mg; ergotamine tartrate 2mg - suppository - 0.25/100/100/2mg - active: atropa belladonna 0.25mg butalbital 100mg caffeine 100mg ergotamine tartrate 2mg
cafergot pb
novartis new zealand ltd - atropa belladonna 0.25mg; butalbital 100mg; caffeine 100mg; ergotamine tartrate 2mg - suppository - 0.25/100/2/100mg - active: atropa belladonna 0.25mg butalbital 100mg caffeine 100mg ergotamine tartrate 2mg
migril tablets
wockhardt uk ltd - ergotamine tartrate; cyclizine hydrochloride; caffeine hydrate - oral tablet - 2mg ; 50mg ; 100mg
diergo spray 4 mg/ml nas. spray sol. spray cont.
amdipharm ltd. - dihydroergotamine mesilate 4 mg/ml - nasal spray, solution - 4 mg/ml - dihydroergotamine mesilate 4 mg/ml - dihydroergotamine
cafergot 1 mg tab tablet
novartis - caffeine, ergotamine tartrate - tablet - 1 , 100 mg
cafergot 1 mg tab tablet
amdipharma, ireland - caffeine,ergotamine tartrate,hydrochlorothiazide,eprosartan mesilate - tablet - 100,1,12.5,600 mg,